Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill
Weight-loss treatments need to become cheaper, easier to take and lead to less reduction in muscle mass, according to the chief executive of AstraZeneca, which is working with a Chinese company to develop a pill to tackle obesity and type 2 diabetes.
In November, Britain’s biggest drugmaker struck an exclusive licence agreement with Shanghai-based Eccogene, for an experimental drug called ECC5004 that would also treat cardiometabolic conditions such as heart disease and stroke. Obesity and diabetes affect more than 1 billion people globally.
